Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Short Interest Update

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) was the recipient of a large decline in short interest during the month of July. As of July 15th, there was short interest totaling 340,264 shares, a decline of 95.7% from the June 30th total of 7,845,889 shares. Based on an average daily trading volume, of 2,998,595 shares, the short-interest ratio is presently 0.1 days. Approximately 0.3% of the company’s stock are sold short.

Catalyst Pharmaceuticals Price Performance

CPRX remained flat at $31.49 during trading on Friday. The company’s 50 day simple moving average is $31.39 and its 200-day simple moving average is $27.30. Catalyst Pharmaceuticals has a fifty-two week low of $19.05 and a fifty-two week high of $32.56. The firm has a market cap of $3.86 billion, a PE ratio of 18.10, a PEG ratio of 0.96 and a beta of 0.74.

Wall Street Analysts Forecast Growth

CPRX has been the topic of several analyst reports. Robert W. Baird cut shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 7th. Citigroup downgraded Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their target price for the company from $35.00 to $31.50 in a research report on Friday, May 8th. Weiss Ratings upgraded Catalyst Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a report on Wednesday, June 3rd. Wall Street Zen cut Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, May 9th. Finally, HC Wainwright downgraded Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their price target for the company from $35.00 to $31.50 in a research note on Thursday, May 28th. Two equities research analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $32.00.

Institutional Investors Weigh In On Catalyst Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the company. Royal Bank of Canada grew its holdings in Catalyst Pharmaceuticals by 39.1% during the first quarter. Royal Bank of Canada now owns 213,469 shares of the biopharmaceutical company’s stock worth $5,177,000 after purchasing an additional 60,040 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Catalyst Pharmaceuticals by 5.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 72,052 shares of the biopharmaceutical company’s stock valued at $1,749,000 after buying an additional 3,800 shares during the period. Goldman Sachs Group Inc. raised its stake in Catalyst Pharmaceuticals by 11.9% in the first quarter. Goldman Sachs Group Inc. now owns 3,135,473 shares of the biopharmaceutical company’s stock valued at $76,035,000 after buying an additional 333,100 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of Catalyst Pharmaceuticals by 99.4% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 526,297 shares of the biopharmaceutical company’s stock valued at $12,763,000 after buying an additional 262,392 shares during the last quarter. Finally, Intech Investment Management LLC lifted its position in shares of Catalyst Pharmaceuticals by 6.5% in the first quarter. Intech Investment Management LLC now owns 70,087 shares of the biopharmaceutical company’s stock valued at $1,700,000 after buying an additional 4,261 shares during the last quarter. 79.22% of the stock is owned by institutional investors.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).